- SynonymIL18BP,IL18BPa,Tadekinig-alfa
- SourceHuman IL-18BP, Fc Tag (ILP-H5253) is expressed from human 293 cells (HEK293). It contains AA Thr 31 - Gly 194 (Accession # NP_001138529).Predicted N-terminus: Thr 31Request for sequence
- Molecular Characterization
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 44.3 kDa. The protein migrates as 56-66 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
- EndotoxinLess than 1.0 EU per μg by the LAL method.
- Purity
>95% as determined by SDS-PAGE.
- Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
- Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
- Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human IL-18BP, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
- BackgroundInterleukin-18-binding protein (IL18BP) is also known as Tadekinig-alfa, IL18BPa, which functions as an IL18 inhibitor. IL18BP is a secreted protein which contains one Ig-like C2-type (immunoglobulin-like) domain. IL18BP does not have a transmembrane domain and hence is not anchored to the cell membrane. IL18BP is strongly expressed in heart, lung, placenta and spleen. Isoform A of IL18BP binds to IL-18 and inhibits its activity. IL18BP also functions as an inhibitor of the early TH1 cytokine response. IL18BP suppresses the production of IFN-gamma resulting in reduced T-helper type 1 immune responses.
- References
- (1)Novick D., et al., 1999, Immunity 10:127-136.
- (2)Aizawa Y., et al., 1999, FEBS Lett. 445:338-342.
- (3)Halim A., et al., 2011, Mol. Cell. Proteomics 0:0-0.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
